Cue Biopharma Inc illékonyság
Mi az Cue Biopharma Inc illékonyság?
A illékonyság az Cue Biopharma Inc - 13.95%
Mi a illékonyság meghatározása?
A volatilitás vagy az átlagos valódi tartomány százalék (ATRP 14) a záróár százalékában kifejezve.
Average true range percent (ATRP) measures volatility on a relative level. This is opposed to the ATR, which measures volatility on an absolute level. ATRP allows securities to be compared whereas ATR does not. That means lower-priced stocks won't necessarily have lower ATR values than higher-priced stocks.
The period used in the calculation is 14 days and the normalized indicator oscillates between 0 and 100 percent of recent price variation. Importantly, the indicator doesn't predict the direction of price but it describes the current volatility. The volatility is comparable across all securities and all markets.
Volatility expresses the degree of price movement. The use of ATRP as volatility compared to ATR is preferred in cases when different securities or different time periods are compared. Examples are stock screening, filtering strategies, and studying seasonality and volatility patterns over long periods of time and different markets
illékonyság a Health Care szektor a NASDAQ-on cégekben a Cue Biopharma Inc -hoz képest
Mit csinál Cue Biopharma Inc?
cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci
illékonyság -hoz hasonló cégek Cue Biopharma Inc
- Biosynex Bsar nak illékonyság 13.92% van
- Koss nak illékonyság 13.92% van
- Aruma Resources nak illékonyság 13.92% van
- Torchlight Resources Inc nak illékonyság 13.93% van
- Titan Medical nak illékonyság 13.93% van
- Surefire Resources NL nak illékonyság 13.94% van
- Cue Biopharma Inc nak illékonyság 13.95% van
- ATOS SE nak illékonyság 13.96% van
- Schroder Japan Growth Fund nak illékonyság 13.96% van
- McKesson Europe AG nak illékonyság 13.96% van
- East Stone Acquisition nak illékonyság 13.96% van
- The Tinley Beverage Co nak illékonyság 13.97% van
- Cerberus Cyber Sentinel nak illékonyság 13.97% van